Pyrazinoate Excretion in the Chimpanzee. RELATION TO URATE DISPOSITION AND THE ACTIONS OF URICOSURIC DRUGS
Authors:
- George M. FanelliGFGeorge M. Fanelli
- I. M. WeinerIWI. M. Weiner
Open Access
- 1 August 1973
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 52 (8) , 1946-1957
Abstract
These experiments were designed to define the renal disposition of pyrazinoic acid in a nonhuman primate that is phylogenetically close to man and to relate this to the effects of pyrazinoate on urate excretion. The renal clearance of pyrazinoate was almost always greater than the simultaneous glomerular filtration rate at plasma concentrations ranging from 1.9 to 960 μg/ml. Some inhibitors of tubular secretion, probenecid, MK-282 (an experimental, potent uricosuric drug), p-aminohippurate, iodopyracet, sulfinpyrazone, and mersalyl, reduced clearances of pyrazinoate to values far below filtration rate. Chlorothiazide, allopurinol, and salicylate did not. The clearance of pyrazinoate was not influenced by changes in urine flow. It is concluded that pyrazinoate is actively secreted and actively reabsorbed. Pyrazinoate had a dual effect on urate excretion. At concentrations in plasma less than 10 μg/ml there was a concentration related fall in urate/inulin clearance ratio, reaching values of 10-20% of control. Over the range of 10-100 μg/ml in plasma, the clearance of urate remained maximally depressed. At higher concentrations of pyrazinoate there was a concentration related increase in urate/inulin clearance ratio such that at pyrazinoate levels above 600 μg/ml a definite uricosuric response was obtained. Prior administration of pyrazinoate to give plasma levels of 20-140 μg/ml completely or almost completely prevented uricosuric responses to probenecid, PAH, chlorothiazide, and sulfinpyrazone. Iodopyracet, mersalyl, salicylate and N-acetyl-4-dibutylsulfamoyl-3-trifluoromethylbenzenesulfonamide (MK-282) retained significant uricosuric action, but the activities were probably less than normal. The results are consistent with a model of urate transport involving high rates of bidirectional transtubular flux.Keywords
This publication has 41 references indexed in Scilit:
- PHARMACOLOGY OF PYRAZINAMIDE: METABOLIC AND RENAL FUNCTION STUDIES RELATED TO THE MECHANISM OF DRUG-INDUCED URATE RETENTIONThe Journal of Pharmacology and Experimental Therapeutics, 1972
- URICOSURIC POTENCY OF 2-SUBSTITUTED ANALOGS OF PROBENECIDThe Journal of Pharmacology and Experimental Therapeutics, 1972
- RENAL EXCRETION AND URICOSURIC PROPERTIES OF HALOFENATE, A HYPOLIPIDEMIC-URICOSURIC AGENT, IN THE CHIMPANZEEThe Journal of Pharmacology and Experimental Therapeutics, 1972
- Renal excretion of uric acid in the dogAmerican Journal of Physiology-Legacy Content, 1968
- Etude chez l’homme de la cinétique d’apparition dans l’urine de l’acide urique 2 14CNephron, 1968
- Uricosuric Drugs, with Special Reference to Probenecid and Sulfinpyrazone1966
- STUDY OF THE PARADOXICAL EFFECTS OF SALICYLATE IN LOW, INTERMEDIATE AND HIGH DOSAGE ON THE RENAL MECHANISMS FOR EXCRETION OF URATE IN MAN *Journal of Clinical Investigation, 1959
- THE ULTRAFILTRABLE CALCIUM OF HUMAN SERUM. I. ULTRAFILTRATION METHODS AND NORMAL VALUES 1Journal of Clinical Investigation, 1957
- A POTENT NEW URICOSURIC AGENT, THE SULFOXIDE METABOLITE OF THE PHENYLBUTAZONE ANALOGUE, G-25671The Journal of Pharmacology and Experimental Therapeutics, 1957
- THE MEASUREMENT OF THE TUBULAR EXCRETORY MASS, EFFECTIVE BLOOD FLOW AND FILTRATION RATE IN THE NORMAL HUMAN KIDNEYJournal of Clinical Investigation, 1938